CRISPR (pronounced “crisper”) and CAR T-cell therapy are genetic technologies that have generated continued excitement during the last several years. Both technologies are experiencing exponential growth. While CAR T-cell therapy holds great promise in the fight against cancer, significant hurdles remain preventing realization of its full potential. Several innovative approaches are under investigation to overcome these hurdles. The present article provides a peek into this area of innovation by focusing on the invention described in a recently published patent application, WO/2018/115887, relating to novel CAR T-cells engineered using CRISPR.
The post CRISPR Modified CAR T-Cells Bolster Immuno Oncology Arsenal appeared first on IPWatchdog.com | Patents & Patent Law.
Patent
- Enablement
- Fee Shifting
- Litigation
- Game On: How IP Helps the Video Game Industry Level Up
- CAFC Affirms District Court Section 101 Dismissal in Patent Infringement Suit Brought Against Samsung/Apple; Newman Dissents
- CAFC Remands Walker Process Antitrust Issue to Fifth Circuit under Xitronex I Precedent
- Geltor is seeking a Senior Patent Agent
- Other Barks & Bites for Friday, June 11: EU Parliament Calls for TRIPS Patent Waiver, Innovation and Competition Act Passes Senate, and Foreign Lawyers Can Now Sit for China’s Patent Bar
Recent Posts
- Game On: How IP Helps the Video Game Industry Level Up
- CAFC Affirms District Court Section 101 Dismissal in Patent Infringement Suit Brought Against Samsung/Apple; Newman Dissents
- CAFC Remands Walker Process Antitrust Issue to Fifth Circuit under Xitronex I Precedent
- Geltor is seeking a Senior Patent Agent
- Other Barks & Bites for Friday, June 11: EU Parliament Calls for TRIPS Patent Waiver, Innovation and Competition Act Passes Senate, and Foreign Lawyers Can Now Sit for China’s Patent Bar